SEC Comment Letter 0000000000-23-001326 to ONCOLYZE, INC. (CIK 0001917375)
ONCOLYZE, INC. (CIK 0001917375)
Date: Feb. 8, 2023 · CIK: 0001917375 · Accession: 0000000000-23-001326
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-11890
Letter
United States securities and exchange commission logo February 8, 2023 Steven J. Evans, MD Chief Executive Officer Oncolyze, Inc. 845 UN Plaza, 61b New York, NY 10017 Re:Oncolyze, Inc. Post-Qualification Amendment to Offering Statement on Form 1-A Filed on February 2, 2023 Post-Qualification Amendment to Offering Statement on Form 1-A Filed February 6, 2023 File No. 024-11890 Dear Steven J. Evans: This is to advise you that we do not intend to review your amendments. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeanne Campanelli
Show Raw Text
United States securities and exchange commission logo
February 8, 2023
Steven J. Evans, MD
Chief Executive Officer
Oncolyze, Inc.
845 UN Plaza, 61b
New York, NY 10017
Re:Oncolyze, Inc.
Post-Qualification Amendment to Offering Statement on Form 1-A
Filed on February 2, 2023
Post-Qualification Amendment to Offering Statement on Form 1-A
Filed February 6, 2023
File No. 024-11890
Dear Steven J. Evans:
This is to advise you that we do not intend to review your amendments.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeanne Campanelli